Try our Advanced Search for more refined results

In Re: Nexium (Esomeprazole) Antitrust Litigation

Track this case

Case overview

Case Number:

1:12-md-02409

Court:

Massachusetts

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

William G. Young

Firms

Companies

Sectors & Industries:

  1. October 02, 2014

    Covington Atty Takes Fire For Bucking Nexium Trial Subpoena

    The plaintiffs in an upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC and others over Nexium fired back Thursday against a Covington & Burling LLP attorney's attempt to avoid testifying via live video feed, saying he offered "no legitimate grounds" to quash the subpoena.

  2. September 29, 2014

    Cos. Try To Nix More Experts In Nexium Pay-For-Delay Suit

    AstraZeneca PLC and two generic drugmakers on Monday pushed a Massachusetts federal court to block two pharmaceutical industry experts from testifying at an upcoming pay-for-delay antitrust class action trial over heartburn drug Nexium, accusing the plaintiffs of trying to rehash discredited arguments.

  3. September 25, 2014

    Judge Won't Exclude Experts In Nexium Pay-For-Delay Trial

    A Massachusetts federal judge on Thursday refused to bar two experts from testifying at an upcoming pay-for-delay antitrust class action trial in multidistrict litigation against AstraZeneca PLC and Teva Pharmaceutical Industries Ltd. over the heartburn drug Nexium, after the parties argued about the reliability of the experts' opinions.

  4. September 24, 2014

    Nexium Buyers Fight Bid To Nix Experts In Pay-For-Delay Trial

    Plaintiffs in an upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC and Teva Pharmaceutical Industries Ltd. over the heartburn drug Nexium on Tuesday shot back at the companies' attempt to exclude expert testimony, saying the experts' opinions are comprehensive and reliable.

  5. September 22, 2014

    Covington Atty Seeks To Escape Subpoena In Nexium MDL

    A Covington & Burling LLP attorney blasted a bid by plaintiffs in an upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC and others over the heartburn drug Nexium to force him to offer live testimony via video feed, saying that a prerecorded deposition should suffice. 

  6. September 15, 2014

    Teva, AstraZeneca Want Expert Nixed From Nexium Trial

    Drugmakers Teva Pharmaceutical Industries Ltd. and AstraZeneca PLC on Friday asked a Massachusetts federal judge to bar a pharmaceutical expert from testifying at an upcoming pay-for-delay antitrust class action trial over Nexium, saying the witness' calculation of reasonable royalty rates was unreliable.

  7. September 03, 2014

    Ranbaxy Fights Doc Bid In Nexium Pay-For-Delay Fight

    Generic-drug maker Ranbaxy Inc. on Tuesday told a Massachusetts federal court it did not need to turn over additional documents ahead of a trial in a pay-for-delay multidistrict litigation involving the heartburn drug Nexium, saying direct-purchaser plaintiffs' supplement production request ignores recent court decisions and federal rules.

  8. August 26, 2014

    Teva, AstraZeneca Say Court Rulings Kill Nexium Delay Suit

    Drugmakers Teva Pharmaceutical Industries Ltd. and AstraZeneca PLC on Monday asked a Massachusetts federal judge to toss claims that Teva purposely delayed marketing a generic version of Nexium by two years, saying the judge's recent rulings blow a hole in a class of drug buyers' antitrust suit against the companies.

  9. August 20, 2014

    Nexium Buyers Say Ranbaxy Should Turn Over Docs In MDL

    Direct-purchaser plaintiffs in the pay-for-delay multidistrict litigation involving the heartburn drug Nexium on Tuesday asked a Massachusetts federal judge to compel generic-drug maker Ranbaxy Inc. to carry out supplemental production of documents ahead of an October trial, saying that the request is not burdensome.

  10. March 21, 2014

    Teva Bashes Buyers' Expert In Bid To Uphold Antitrust Win

    Teva Pharmaceutical Industries Ltd. on Thursday urged a Massachusetts federal judge to uphold its win in a pay-for-delay class action involving the heartburn drug Nexium, asserting that the direct purchaser class plaintiffs' expert witness had not presented any solid evidence of illicit payment or reasonable damages.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!